228:
29:
446:"Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade"
444:
Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE (June 2018).
298:
312:
340:
InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
501:
332:
61:
412:
147:
394:
207:
370:
41:
223:
82:
432:
196:
477:
136:
467:
457:
244:
91:
156:
227:
472:
445:
358:(LY2157299) is a small molecular experimental cancer drug previously in development by
366:
inhibitor. Development of galunisertib by Eli Lilly was discontinued in
January 2020.
495:
116:
427:
462:
274:
127:
20:
431:
for "A Study of LY2157299 in
Participants With Hepatocellular Carcinoma" at
359:
481:
28:
102:
369:
Galunisertib was investigated in a phase II trial for treatment of
176:
374:
363:
297:
288:
187:
167:
212:
320:
N1=CC=C(C2=CC(=CC=C12)C(=O)N)C1=C2N(N=C1C1C=CC=C(N=1)C)CCC2
377:
blockade resulted in improved tumor growth inhibition.
373:. Pre-clinically, combination of galunisertib with
286:
273:
243:
238:
206:
186:
166:
146:
126:
101:
81:
73:-pyrrolo(1,2-b)pyrazol-3-yl)-6-quinolinecarboxamide
52:
40:
35:
413:"Eli Lilly cuts 3 cancer drugs amid Q4 clear-out"
115:
90:
8:
19:
226:
135:
27:
471:
461:
155:
69:4-(5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4
386:
337:
317:
222:
66:
18:
395:"Lilly Oncology Pipeline - Lilly USA"
195:
7:
450:Journal for Immunotherapy of Cancer
175:
106:
14:
261:
255:
345:Key:IVRXNBXKWIJUQB-UHFFFAOYSA-N
267:
249:
1:
399:www.lillyoncologypipeline.com
518:
239:Chemical and physical data
502:Experimental cancer drugs
463:10.1186/s40425-018-0356-4
328:
308:
57:
26:
371:hepatocellular carcinoma
425:Clinical trial number
23:
433:ClinicalTrials.gov
353:
352:
299:Interactive image
208:CompTox Dashboard
16:Chemical compound
509:
486:
485:
475:
465:
441:
435:
423:
417:
416:
409:
403:
402:
391:
301:
281:
269:
263:
257:
251:
231:
230:
216:
214:
199:
179:
159:
139:
119:
109:
108:
94:
31:
24:
22:
517:
516:
512:
511:
510:
508:
507:
506:
492:
491:
490:
489:
443:
442:
438:
424:
420:
411:
410:
406:
393:
392:
388:
383:
349:
346:
341:
336:
335:
324:
321:
316:
315:
304:
279:
266:
260:
254:
234:
210:
202:
182:
162:
142:
122:
105:
97:
77:
74:
65:
64:
43:
17:
12:
11:
5:
515:
513:
505:
504:
494:
493:
488:
487:
436:
418:
404:
385:
384:
382:
379:
351:
350:
348:
347:
344:
342:
339:
331:
330:
329:
326:
325:
323:
322:
319:
311:
310:
309:
306:
305:
303:
302:
294:
292:
284:
283:
277:
271:
270:
264:
258:
252:
247:
241:
240:
236:
235:
233:
232:
224:DTXSID00220362
219:
217:
204:
203:
201:
200:
192:
190:
184:
183:
181:
180:
172:
170:
164:
163:
161:
160:
152:
150:
144:
143:
141:
140:
132:
130:
124:
123:
121:
120:
112:
110:
99:
98:
96:
95:
87:
85:
79:
78:
76:
75:
68:
60:
59:
58:
55:
54:
50:
49:
46:
44:administration
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
514:
503:
500:
499:
497:
483:
479:
474:
469:
464:
459:
455:
451:
447:
440:
437:
434:
430:
429:
422:
419:
414:
408:
405:
400:
396:
390:
387:
380:
378:
376:
372:
367:
365:
361:
357:
343:
338:
334:
327:
318:
314:
307:
300:
296:
295:
293:
290:
285:
278:
276:
272:
248:
246:
242:
237:
229:
225:
221:
220:
218:
209:
205:
198:
194:
193:
191:
189:
185:
178:
174:
173:
171:
169:
165:
158:
154:
153:
151:
149:
145:
138:
134:
133:
131:
129:
125:
118:
114:
113:
111:
104:
100:
93:
89:
88:
86:
84:
80:
72:
67:
63:
56:
51:
47:
45:
39:
36:Clinical data
34:
30:
25:
453:
449:
439:
426:
421:
407:
398:
389:
368:
356:Galunisertib
355:
354:
197:CHEBI:137064
70:
21:Galunisertib
428:NCT01246986
282: g·mol
92:700874-72-2
53:Identifiers
381:References
362:. It is a
287:3D model (
275:Molar mass
157:3OKH1W5LZE
128:ChemSpider
83:CAS Number
62:IUPAC name
456:(1): 47.
360:Eli Lilly
42:Routes of
496:Category
482:29866156
117:10090485
473:5987416
280:369.428
245:Formula
137:8266022
103:PubChem
480:
470:
313:SMILES
177:D10437
375:PD-L1
364:TGF-b
333:InChI
289:JSmol
188:ChEBI
478:PMID
168:KEGG
148:UNII
468:PMC
458:doi
213:EPA
107:CID
498::
476:.
466:.
452:.
448:.
397:.
259:19
253:22
48:PO
484:.
460::
454:6
415:.
401:.
291:)
268:O
265:5
262:N
256:H
250:C
215:)
211:(
71:H
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
